HK1062457A1 - Modified and stabilized gdf propeptides and uses thereof - Google Patents
Modified and stabilized gdf propeptides and uses thereofInfo
- Publication number
- HK1062457A1 HK1062457A1 HK04104973A HK04104973A HK1062457A1 HK 1062457 A1 HK1062457 A1 HK 1062457A1 HK 04104973 A HK04104973 A HK 04104973A HK 04104973 A HK04104973 A HK 04104973A HK 1062457 A1 HK1062457 A1 HK 1062457A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- modified
- gdf propeptides
- stabilized gdf
- stabilized
- propeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26750901P | 2001-02-08 | 2001-02-08 | |
PCT/US2002/003467 WO2002068650A2 (fr) | 2001-02-08 | 2002-02-08 | Propeptides gdf modifies et stabilises et utilisations de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1062457A1 true HK1062457A1 (en) | 2004-11-05 |
Family
ID=23019083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04104973A HK1062457A1 (en) | 2001-02-08 | 2004-07-08 | Modified and stabilized gdf propeptides and uses thereof |
Country Status (23)
Country | Link |
---|---|
US (6) | US7202210B2 (fr) |
EP (1) | EP1397492B1 (fr) |
JP (3) | JP4280071B2 (fr) |
AR (1) | AR032567A1 (fr) |
AT (1) | ATE357519T1 (fr) |
AU (1) | AU2002243852B2 (fr) |
BR (1) | BR0207110A (fr) |
CA (2) | CA2437218A1 (fr) |
CL (1) | CL2009000648A1 (fr) |
CY (1) | CY1106629T1 (fr) |
DE (1) | DE60219006T2 (fr) |
DK (1) | DK1397492T3 (fr) |
ES (1) | ES2284828T3 (fr) |
HK (1) | HK1062457A1 (fr) |
MX (1) | MXPA03007063A (fr) |
NO (1) | NO333427B1 (fr) |
NZ (2) | NZ550297A (fr) |
PL (2) | PL212078B1 (fr) |
PT (1) | PT1397492E (fr) |
SG (2) | SG165982A1 (fr) |
TW (2) | TW200526779A (fr) |
WO (1) | WO2002068650A2 (fr) |
ZA (2) | ZA200508954B (fr) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
KR20040096592A (ko) * | 2002-02-21 | 2004-11-16 | 와이어쓰 | 폴리스타틴 도메인을 포함하는 단백질 |
MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
US20040138118A1 (en) * | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
WO2004083432A1 (fr) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation de la reconnaissance d'exons dans le pre-arnm par interference avec la structure d'arn secondaire |
CA2526669A1 (fr) * | 2003-06-02 | 2004-12-16 | Wyeth | Methodes de traitement et de prevention des troubles neuromusculaires |
EP2332977B1 (fr) * | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | Polypeptides du récepteur AvtRII |
WO2006020884A2 (fr) * | 2004-08-12 | 2006-02-23 | Wyeth | Traitement combine du diabete, de l'obesite et de maladies cardiovasculaires, faisant appel a des inhibiteurs de gdf-8 |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
MX2007011400A (es) * | 2005-03-23 | 2007-10-11 | Wyeth Corp | Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). |
US20060240488A1 (en) * | 2005-03-23 | 2006-10-26 | Nowak John A | Detection of an immune response to GDF-8 modulating agents |
KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
EP2502628B1 (fr) * | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Séquences de polynucléotides et de polypeptides impliquées dans le cancer |
CA2660523C (fr) | 2006-08-11 | 2019-03-19 | Prosensa Technologies B.V. | Procedes et moyens de traitement de troubles genetiques associes a l'instabilite des repetitions de l'adn |
EP2446896A1 (fr) * | 2006-12-18 | 2012-05-02 | Acceleron Pharma, Inc. | Antagonistes de L'Activine-ActRII pour leur utilisation pour accroître les niveaux de globules rouges, pour accroître les niveaux de réticulocytes ou pour promouvoir l'érythropoièse |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
RU2473362C2 (ru) * | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
TWI548647B (zh) * | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EA025371B1 (ru) * | 2007-02-09 | 2016-12-30 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
CN101790385A (zh) * | 2007-07-12 | 2010-07-28 | 普罗森那技术公司 | 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子 |
AU2008273096B2 (en) * | 2007-07-12 | 2013-05-02 | Academisch Ziekenhuis Leiden | Molecules for targeting compounds to various selected organs or tissues |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
BRPI0811317A2 (pt) | 2007-08-03 | 2015-01-27 | Summit Corp Plc | Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação |
EP3243524A1 (fr) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Antagonistes de l'activine-actriia et utilisations pour réduire ou empêcher la sécrétion de fsh |
EP2614827B1 (fr) | 2007-10-26 | 2017-06-28 | Academisch Ziekenhuis Leiden | Moyens et procédé de compensation des troubles musculaires |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
JP2011510678A (ja) * | 2008-02-08 | 2011-04-07 | プロセンサ ホールディング ビーブイ | Dna反復不安定性関連遺伝性障害を治療するための方法及び手段 |
US9119818B2 (en) | 2008-05-14 | 2015-09-01 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
EP2119783A1 (fr) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes |
EP3363453A1 (fr) * | 2008-06-26 | 2018-08-22 | Acceleron Pharma Inc. | Actriia soluble en tant qu'antagoniste activine-actriia pour utilisation dans le traitement de l'anémie ou de maladies osseuses |
LT3494986T (lt) | 2008-08-14 | 2020-07-10 | Acceleron Pharma Inc. | Gdf gaudyklės |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
MX336869B (es) | 2008-11-03 | 2016-02-04 | Alethia Biotherapeutics Inc | Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor. |
WO2010083034A1 (fr) * | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Procédés permettant d'augmenter l'adiponectine |
EP2421971B1 (fr) | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucléotides comportant une inosine pour le traitement de dmd |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
KR20190090049A (ko) | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
IN2012DN02766A (fr) * | 2009-09-09 | 2015-09-18 | Acceleron Pharma Inc | |
JP5836961B2 (ja) * | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ, インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
TW201120210A (en) | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
ES2616561T3 (es) | 2009-12-24 | 2017-06-13 | Biomarin Technologies B.V. | Molécula para tratar un trastorno inflamatorio |
CA2807607A1 (fr) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Culture cellulaire de cellules adaptees exemptes de facteur de croissance |
US20120121576A1 (en) | 2010-11-08 | 2012-05-17 | Jasbir Seehra | Actriia binding agents and uses thereof |
KR101993259B1 (ko) | 2011-03-31 | 2019-06-27 | 에이디씨 테라퓨틱스 에스에이 | 신장 결합 항원 1에 대한 항체 및 이의 항원 결합 단편 |
SG11201401220SA (en) | 2011-10-21 | 2014-07-30 | Pfizer | Addition of iron to improve cell culture |
DK2802351T3 (da) | 2012-01-09 | 2019-05-13 | Adc Therapeutics Sa | Midler til behandling af triple-negativ brystkræft |
EP4043039A1 (fr) | 2012-01-27 | 2022-08-17 | BioMarin Technologies B.V. | Oligonucléotides de modulation arn ayant des caractéristiques améliorées pour le traitement de la dystrophie musculaire de duchenne et becker |
EP2830646B1 (fr) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques |
AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
WO2014000042A1 (fr) * | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | Compositions et procédés pour modifier des ligands de la famille du tgf-β |
CA2880649C (fr) | 2012-08-01 | 2023-03-14 | Elizabeth MCNALLY | Reduction des lesions tissulaires et de la fibrose via la proteine-4 de liaison au tgf beta latent (ltbp4) |
WO2014062535A1 (fr) | 2012-10-15 | 2014-04-24 | Bristol-Myers Squibb Company | Procédés de culture de cellules de mammifères en vue de la production de protéines |
NZ747350A (en) | 2012-10-24 | 2020-07-31 | Celgene Corp | Methods for treating anemia |
CN113604550A (zh) * | 2012-10-24 | 2021-11-05 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
CA2890217C (fr) | 2012-11-02 | 2021-07-20 | Yifu FANG | Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres |
WO2014120619A2 (fr) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions et procédés à utiliser pour le traitement de troubles métaboliques |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
JP6143270B2 (ja) * | 2013-01-31 | 2017-06-07 | 学校法人東京薬科大学 | マイオスタチン阻害ペプチド |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
PT3027642T (pt) * | 2013-07-31 | 2020-10-30 | Amgen Inc | Construtos do fator 15 de diferenciação de crescimento (gdf-15) |
CN104725513A (zh) * | 2013-12-20 | 2015-06-24 | 中国科学院上海生命科学研究院 | 融合蛋白及其在治疗多发性硬化中的用途 |
AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
CN106573966B (zh) | 2014-07-30 | 2022-03-01 | Ngm生物制药有限公司 | 用于治疗代谢异常的组合物和方法 |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
WO2020132647A1 (fr) | 2018-12-21 | 2020-06-25 | Northwestern University | Utilisation d'annexines dans la prévention et le traitement d'une lésion de la membrane musculaire |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
EP0105014B1 (fr) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Rétablissement de tissu chez les animaux |
US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
CA1341617C (fr) | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibine extracte de liquide folliculaire ovarien |
UA39161C2 (uk) | 1984-07-06 | 2001-06-15 | Новартіс Аг | Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують |
ATE128715T1 (de) | 1984-07-16 | 1995-10-15 | Celtrix Pharma | Polypeptide induzierende faktoren in knochen und knorpel. |
US4740587A (en) | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
NZ231899A (en) | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
US4798885A (en) | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
US5215893A (en) | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US4737578A (en) | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Factors that soak bone formation |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
AU645244B2 (en) | 1988-04-08 | 1994-01-13 | Genetics Institute, Llc | Bone and cartilage inductive compositions |
US5071834A (en) | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
ATE162223T1 (de) | 1989-03-28 | 1998-01-15 | Genetics Inst | Osteoinduktive zusammensetzungen |
EP0394827A1 (fr) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Polypeptides chimériques de CD4-immunoglobuline |
CA2020729A1 (fr) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Proteine morphogenetique des os |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
US5166190A (en) | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
JPH06500991A (ja) | 1990-05-16 | 1994-01-27 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨および軟骨誘導蛋白質 |
EP0550625B1 (fr) | 1990-09-26 | 2003-11-05 | Genetics Institute, LLC | Derives bmp-5 |
AU651421B2 (en) | 1990-11-30 | 1994-07-21 | Celtrix Pharmaceuticals, Inc. | Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair |
US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
AU662155B2 (en) | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
ATE175441T1 (de) | 1991-06-25 | 1999-01-15 | Genetics Inst | Bmp-9 zusammensetzungen |
AU661854B2 (en) * | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5171579A (en) | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
WO1993009229A1 (fr) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Proteines heterodimeres morphogenetiques d'os de recombinaison, compositions et procedes d'utilisation |
ATE242639T1 (de) | 1992-07-31 | 2003-06-15 | Curis Inc | Morphogen induzierte nerven wiederherstellung und wiedergutmachung. |
US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
CA2157577C (fr) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Facteur-8 de differentiation de croissance |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
DK1378572T3 (da) | 1993-05-12 | 2007-02-05 | Genetics Inst Llc | BMP-11-sammensætninger |
WO1995005846A1 (fr) | 1993-08-26 | 1995-03-02 | Genetics Institute, Inc. | Regeneration nerveuse utilisant des proteines morphogenetiques osseuses chez l'homme |
US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
ATE305036T1 (de) | 1994-07-08 | 2005-10-15 | Univ Johns Hopkins Med | Wachstums-differenzierungsfaktor-11 |
US5466190A (en) * | 1994-07-25 | 1995-11-14 | Deere & Company | Precleaner for a cleaning shoe |
US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
JPH10262688A (ja) * | 1994-11-30 | 1998-10-06 | Univ Rockefeller | 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途 |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
ATE244574T1 (de) | 1996-03-22 | 2003-07-15 | Curis Inc | Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
US6696557B1 (en) * | 1996-04-19 | 2004-02-24 | Genentech, Inc. | AL-2 neurotrophic factor nucleic acid |
PE99498A1 (es) * | 1996-07-26 | 1999-01-21 | Novartis Ag | Polipeptidos de fusion |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
PT2045322E (pt) * | 1997-07-14 | 2015-10-16 | Université de Liège | Musculatura dupla em mamíferos |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
GB2345397B (en) * | 1997-08-19 | 2001-10-31 | Citizen Watch Co Ltd | Piezoelectric vibrator |
US6372454B2 (en) | 1997-08-29 | 2002-04-16 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding Follistatin-3 |
AU1276399A (en) * | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
WO1999024618A1 (fr) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Procedes de detection de mutations dans des variants de myostatine |
AU2586199A (en) | 1998-02-05 | 1999-08-23 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
WO2000011163A1 (fr) * | 1998-08-20 | 2000-03-02 | Regeneron Pharmaceuticals, Inc. | Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications |
JP2003517580A (ja) * | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
WO2000073337A1 (fr) * | 1999-06-01 | 2000-12-07 | Biogen, Inc. | Conjugues polymeres de proteines hedgehog et leurs utilisations |
AU778470B2 (en) | 1999-07-20 | 2004-12-09 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
AU2001241817A1 (en) | 2000-02-29 | 2001-09-12 | Zymogenetics Inc. | Kunitz domain polypeptide zkun8 |
US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
PL350983A1 (en) * | 2001-11-30 | 2003-06-02 | Advanced Digital Broadcast Ltd | Method of scanning a high-frequency signal band and apparatus therefor |
KR20040096592A (ko) | 2002-02-21 | 2004-11-16 | 와이어쓰 | 폴리스타틴 도메인을 포함하는 단백질 |
MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
US20040138118A1 (en) | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7511012B2 (en) | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
CA2526669A1 (fr) | 2003-06-02 | 2004-12-16 | Wyeth | Methodes de traitement et de prevention des troubles neuromusculaires |
MX2007011400A (es) | 2005-03-23 | 2007-10-11 | Wyeth Corp | Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). |
US20060240488A1 (en) | 2005-03-23 | 2006-10-26 | Nowak John A | Detection of an immune response to GDF-8 modulating agents |
-
2002
- 2002-02-07 TW TW094108366A patent/TW200526779A/zh unknown
- 2002-02-07 TW TW091102268A patent/TWI329129B/zh not_active IP Right Cessation
- 2002-02-08 BR BR0207110-0A patent/BR0207110A/pt not_active IP Right Cessation
- 2002-02-08 JP JP2002568744A patent/JP4280071B2/ja not_active Expired - Fee Related
- 2002-02-08 ZA ZA200508954A patent/ZA200508954B/en unknown
- 2002-02-08 NZ NZ550297A patent/NZ550297A/en not_active IP Right Cessation
- 2002-02-08 ES ES02709366T patent/ES2284828T3/es not_active Expired - Lifetime
- 2002-02-08 AR ARP020100421A patent/AR032567A1/es not_active Application Discontinuation
- 2002-02-08 WO PCT/US2002/003467 patent/WO2002068650A2/fr active IP Right Grant
- 2002-02-08 PL PL390369A patent/PL212078B1/pl unknown
- 2002-02-08 AT AT02709366T patent/ATE357519T1/de active
- 2002-02-08 NZ NZ527286A patent/NZ527286A/en not_active IP Right Cessation
- 2002-02-08 PL PL372888A patent/PL207202B1/pl unknown
- 2002-02-08 MX MXPA03007063A patent/MXPA03007063A/es active IP Right Grant
- 2002-02-08 US US10/071,499 patent/US7202210B2/en not_active Expired - Fee Related
- 2002-02-08 EP EP02709366A patent/EP1397492B1/fr not_active Expired - Lifetime
- 2002-02-08 SG SG200506783-0A patent/SG165982A1/en unknown
- 2002-02-08 CA CA002437218A patent/CA2437218A1/fr not_active Abandoned
- 2002-02-08 SG SG2010040194A patent/SG187989A1/en unknown
- 2002-02-08 DE DE60219006T patent/DE60219006T2/de not_active Expired - Lifetime
- 2002-02-08 CA CA002674673A patent/CA2674673A1/fr not_active Abandoned
- 2002-02-08 DK DK02709366T patent/DK1397492T3/da active
- 2002-02-08 AU AU2002243852A patent/AU2002243852B2/en not_active Ceased
- 2002-02-08 PT PT02709366T patent/PT1397492E/pt unknown
-
2003
- 2003-08-04 NO NO20033456A patent/NO333427B1/no not_active IP Right Cessation
- 2003-08-06 ZA ZA200306064A patent/ZA200306064B/en unknown
-
2004
- 2004-07-08 HK HK04104973A patent/HK1062457A1/xx not_active IP Right Cessation
-
2005
- 2005-07-19 JP JP2005209321A patent/JP2006001938A/ja not_active Withdrawn
-
2006
- 2006-12-21 US US11/614,702 patent/US7737116B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/614,594 patent/US7560441B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 CY CY20071100719T patent/CY1106629T1/el unknown
-
2008
- 2008-11-21 JP JP2008298812A patent/JP5013618B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-18 CL CL2009000648A patent/CL2009000648A1/es unknown
- 2009-05-04 US US12/434,758 patent/US8222384B2/en not_active Expired - Fee Related
-
2012
- 2012-06-14 US US13/523,391 patent/US8710025B2/en not_active Expired - Fee Related
-
2013
- 2013-09-19 US US14/032,079 patent/US20140228289A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1062457A1 (en) | Modified and stabilized gdf propeptides and uses thereof | |
EP1463742A4 (fr) | Nouvelles pyrazolo-pyrimidines et pyrrolo-pyrimidines et leur utilisation | |
HK1078266A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | |
IL164021A0 (en) | Antibodies and anti-pharmaceutical compositions containing the same | |
EP1539941A4 (fr) | Adzymes et leurs utilisations | |
EP1408978A4 (fr) | Nouvelles phenylamino-pyrimidines et leur utilisation | |
IL156161A0 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors | |
AU2002305523A1 (en) | Dioxanes and uses thereof | |
IL154553A0 (en) | Urocortin-iii and uses thereof | |
GB0126889D0 (en) | Compounds and their uses | |
GB0114517D0 (en) | Trx1 antibody and uses therefor | |
EP1392317A4 (fr) | 1-benzazepines substituees et leurs derives | |
EP1408985A4 (fr) | Nouveaux pyridopyrimidones et leurs utilisations | |
AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
HUP0401162A3 (en) | Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives | |
IL161387A0 (en) | Rankl mimics and uses thereof | |
AU2002238319A1 (en) | Abcg4 transporter and uses thereof | |
EP1367123A4 (fr) | Neurotonine et utilisation | |
EP1421101A4 (fr) | Glycoproteines p et leurs utilisations | |
AU2003228397A8 (en) | Hausp-p53 interaction and uses thereof | |
AU2003216442A8 (en) | Enkurin and uses thereof | |
AU2002238318A1 (en) | Abca5 transporter and uses thereof | |
GB0026657D0 (en) | The dynowheel and its components | |
AU2002333371A1 (en) | Novel 4-aminofuropyrimidines and the use thereof | |
AU2002256588A1 (en) | Catalase-inactivating compounds and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: ADDITION OF INVENTOR: KATHLEEN N TOMKINSON |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170208 |